JPWO2011125245A1 - ｍｉＲＮＡを用いた小細胞肺癌の予後予測方法、小細胞肺癌治療方法、小細胞肺癌予後改善方法、及び小細胞肺癌治療剤のスクリーニング方法 - Google Patents

ｍｉＲＮＡを用いた小細胞肺癌の予後予測方法、小細胞肺癌治療方法、小細胞肺癌予後改善方法、及び小細胞肺癌治療剤のスクリーニング方法 Download PDF

Info

Publication number
JPWO2011125245A1
JPWO2011125245A1 JP2012509270A JP2012509270A JPWO2011125245A1 JP WO2011125245 A1 JPWO2011125245 A1 JP WO2011125245A1 JP 2012509270 A JP2012509270 A JP 2012509270A JP 2012509270 A JP2012509270 A JP 2012509270A JP WO2011125245 A1 JPWO2011125245 A1 JP WO2011125245A1
Authority
JP
Japan
Prior art keywords
mir
lung cancer
precursor
small cell
cell lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012509270A
Other languages
English (en)
Japanese (ja)
Inventor
石川　雄一
雄一 石川
岳彦 大場
岳彦 大場
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japanese Foundation for Cancer Research
Original Assignee
Japanese Foundation for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japanese Foundation for Cancer Research filed Critical Japanese Foundation for Cancer Research
Publication of JPWO2011125245A1 publication Critical patent/JPWO2011125245A1/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012509270A 2010-04-05 2010-10-05 ｍｉＲＮＡを用いた小細胞肺癌の予後予測方法、小細胞肺癌治療方法、小細胞肺癌予後改善方法、及び小細胞肺癌治療剤のスクリーニング方法 Pending JPWO2011125245A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010087093 2010-04-05
JP2010087093 2010-04-05
PCT/JP2010/067432 WO2011125245A1 (fr) 2010-04-05 2010-10-05 Méthode de prédiction de pronostic de cancer du poumon à petites cellules, méthode de traitement du cancer du poumon à petites cellules, méthode d'amélioration du pronostic du cancer du poumon à petites cellules et méthode de criblage pour la recherche d'un agent thérapeutique pour le cancer du poumon à petites cellules, chacun utilisant les miarn

Publications (1)

Publication Number Publication Date
JPWO2011125245A1 true JPWO2011125245A1 (ja) 2013-07-08

Family

ID=44762220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012509270A Pending JPWO2011125245A1 (ja) 2010-04-05 2010-10-05 ｍｉＲＮＡを用いた小細胞肺癌の予後予測方法、小細胞肺癌治療方法、小細胞肺癌予後改善方法、及び小細胞肺癌治療剤のスクリーニング方法

Country Status (2)

Country Link
JP (1) JPWO2011125245A1 (fr)
WO (1) WO2011125245A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9994843B2 (en) 2013-02-15 2018-06-12 National University Corporation Tokyo Medical And Dental University Method for assaying microRNA, cancer therapeutic agent, and medicinal composition containing same for cancer therapy
CN107384921B (zh) * 2017-07-27 2020-09-15 中国人民解放军总医院 miR216a用于抑制骨肉瘤细胞的增殖、侵袭和迁移
CN112094904B (zh) * 2020-09-30 2022-08-16 中国人民解放军军事科学院军事医学研究院 急性电离辐射早期损伤检测的微生物种水平标志物及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943318B2 (en) * 2006-01-05 2011-05-17 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2008154333A2 (fr) * 2007-06-08 2008-12-18 Asuragen, Inc. Gènes et chemins régulés par mir-34 en tant que cibles pour une intervention thérapeutique
JP5399011B2 (ja) * 2007-06-28 2014-01-29 三菱化学メディエンス株式会社 組織傷害あるいは細胞増殖性疾患の検出方法

Also Published As

Publication number Publication date
WO2011125245A1 (fr) 2011-10-13

Similar Documents

Publication Publication Date Title
JP5624470B2 (ja) ヒト末梢血微小胞におけるｍｉＲＮＡの発現およびその使用
Li et al. Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer
US20090209621A1 (en) Compositions and methods for decreasing microrna expression for the treatment of neoplasia
Zhan et al. MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1
Wu et al. miR-362-5p inhibits proliferation and migration of neuroblastoma cells by targeting phosphatidylinositol 3-kinase-C2β
JP6153932B2 (ja) 骨肉腫のためのマイクロｒｎａに基づく方法およびアッセイ
US20160346311A1 (en) Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
WO2006074367A2 (fr) Procede permettant de predire et de reduire le risque de metastases du cancer du sein dans les poumons
EP2683411B1 (fr) Procédés d'utilisation de microarn-26a destinés à favoriser l'angiogenèse
KR101953300B1 (ko) 탁산계 항암제 내성 암의 진단 및 치료를 위한 조성물, 키트 및 방법
Wang et al. miR-21 is overexpressed in hydatidiform mole tissues and promotes proliferation, migration, and invasion in choriocarcinoma cells
US9994915B2 (en) miR-211 expression and related pathways in human melanoma
CA2879410C (fr) Agent pour le traitement du cancer
WO2011125245A1 (fr) Méthode de prédiction de pronostic de cancer du poumon à petites cellules, méthode de traitement du cancer du poumon à petites cellules, méthode d'amélioration du pronostic du cancer du poumon à petites cellules et méthode de criblage pour la recherche d'un agent thérapeutique pour le cancer du poumon à petites cellules, chacun utilisant les miarn
KR102142791B1 (ko) miR-204 억제제의 골관절염 치료 용도
US8921333B2 (en) Therapeutic agent for tumor
Miao et al. Exosomal circCOL1A2 from cancer cells accelerates colorectal cancer progression via regulating miR-665/LASP1 signal axis
US9631194B2 (en) Methods and compositions for use in treatment of FOXP2-related cancers
WO2010050328A1 (fr) Inhibiteur de métastase de tumeur
US10905708B2 (en) MicroRNA-based methods and assays for osteocarcinoma
JP2020502263A (ja) Ｎｓｃｌｃを有する患者の処置のための薬剤及び応答を予測するための方法
US11260072B2 (en) MicroRNA-based methods and assays for osteocarcinoma
EP2199407A1 (fr) Procédés in vitro et compositions pour le diagnostic et/ou le traitement de l'adénocarcinome
CN110964832A (zh) 肺癌诊断和治疗的靶基因
CN110951888A (zh) 检测及靶向al845472.2的试剂及其在肺癌诊治中的应用